Literature DB >> 8104645

Ligand binding properties of putative beta 3-adrenoceptors compared in brown adipose tissue and in skeletal muscle membranes.

M N Sillence1, N G Moore, G G Pegg, D B Lindsay.   

Abstract

1. The beta-adrenoceptor population was characterized in membrane preparations from rat brown adipose tissue (BAT) and from soleus muscle by use of the radioligand [125I]-iodocyanopindolol ([125I]-ICYP). In addition, atypical binding sites for [125I]-ICYP found in both tissues were examined, and the relationship between these sites and the putative rat beta 3-adrenoceptor is discussed. 2. It was established that BAT membranes host a mixed population of beta 1- and beta 2-adrenoceptors. Of these two sites, 55% showed a high affinity for the beta 1-selective ligand CGP 20712A (pK 8.5), and 45% showed a high affinity for the beta 2-selective antagonist ICI 118551 (pK 8.6). Soleus muscle membranes were found to host a population of beta 2-adrenoceptors, characterized by a high affinity for ICI 118551 (pK 9.1), but beta 1-adrenoceptors could not be detected in this preparation. 5-Hydroxytryptamine receptors were not detected in either preparation. 3. In addition to beta 1- and beta 2-adrenoceptors, atypical binding sites were identified in both tissues using high concentrations of radioligand (0.5-0.6 nM) and in the presence of 1 microM (-)-propranolol. The atypical sites were abundant, representing 80 and 81% of the total [125I]-ICYP binding sites in BAT and soleus muscle respectively. When the pK values for 11 ligands were compared, the correlation coefficient for atypical sites in BAT and soleus muscle was 0.94. 4. The atypical binding sites showed a moderate affinity for (+/-)-cyanopindolol (pK 7.3-7.7), poor stereo selectivity for the (+)- and (-)-enantiomers of alprenolol (<10 fold), and a low affinity for B-adrenoceptor antagonists and partial agonists in the order: (+/-)-cyanopindolol>(-)-alprenolol>(-)-propranolol=(+/-)-ICI 118551>>(+/-)-CGP20712A. The affinity of these ligands for the atypical sites reflects their behaviour in functional studies of putative beta 3-adrenoceptors in rat BAT, white adipose tissue, intestine and colon.5. The atypical sites labelled by [125I]-ICYP were resistant to agonist binding, and while the order of affinity of the agonists BRL 37344> isoprenaline> noradrenaline matches their order of potency at putative beta 3-adrenoceptors, none of these compounds caused displacement of the radioligand at concentrations below 10 microM.6. It is concluded that the atypical binding sites for [125I]-ICYP found in rat BAT and soleus muscle membranes are the same, and that these sites show some relationship to the putative rat beta 3-adrenoceptor identified in functional studies using antagonists. However, under the conditions used in the present study, pK values obtained for beta 3-agonist binding are not useful.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104645      PMCID: PMC2175755          DOI: 10.1111/j.1476-5381.1993.tb13743.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Differentiation of beta-adrenoceptors in right atrium, diaphragm and adipose tissue of the rat, using stereoisomers of propranolol, alprenolol, nifenalol and practolol.

Authors:  H H Harms; J Zaagsma; J de Vente
Journal:  Life Sci       Date:  1977-07-01       Impact factor: 5.037

Review 2.  The brown adipocyte beta-adrenoceptor.

Authors:  J R Arch
Journal:  Proc Nutr Soc       Date:  1989-07       Impact factor: 6.297

3.  Localization and characterization of two propranolol resistant (-) [125I]cyanopindolol binding sites in rat skeletal muscle.

Authors:  P Molenaar; S J Roberts; Y S Kim; H S Pak; R D Sainz; R J Summers
Journal:  Eur J Pharmacol       Date:  1991-12-17       Impact factor: 4.432

4.  Adrenergic receptors of rat esophageal smooth muscle.

Authors:  C K Buckner; R C Christopherson
Journal:  J Pharmacol Exp Ther       Date:  1974-05       Impact factor: 4.030

5.  Molecular cloning and expression of the rat beta 3-adrenergic receptor.

Authors:  J G Granneman; K N Lahners; A Chaudhry
Journal:  Mol Pharmacol       Date:  1991-12       Impact factor: 4.436

6.  Effects of clenbuterol, ICI118551 and sotalol on the growth of cardiac and skeletal muscle and on beta 2-adrenoceptor density in female rats.

Authors:  M N Sillence; M L Matthews; W G Spiers; G G Pegg; D B Lindsay
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

7.  ICI D7114 a novel selective beta-adrenoceptor agonist selectively stimulates brown fat and increases whole-body oxygen consumption.

Authors:  B R Holloway; R Howe; B S Rao; D Stribling; R M Mayers; M G Briscoe; J M Jackson
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

8.  Characterization of beta 1- and beta 2-adrenoceptors in rat skeletal muscles.

Authors:  Y S Kim; R D Sainz; P Molenaar; R J Summers
Journal:  Biochem Pharmacol       Date:  1991-10-09       Impact factor: 5.858

9.  Characterization of catecholamine-mediated relaxations in rat isolated gastric fundus: evidence for an atypical beta-adrenoceptor.

Authors:  D P McLaughlin; A MacDonald
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

10.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

View more
  18 in total

1.  Targeted gene disruption reveals a leptin-independent role for the mouse beta3-adrenoceptor in the regulation of body composition.

Authors:  J P Revelli; F Preitner; S Samec; P Muniesa; F Kuehne; O Boss; J D Vassalli; A Dulloo; J Seydoux; J P Giacobino; J Huarte; C Ody
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Interaction with caveolin-1 modulates G protein coupling of mouse β3-adrenoceptor.

Authors:  Masaaki Sato; Dana S Hutchinson; Michelle L Halls; Sebastian G B Furness; Tore Bengtsson; Bronwyn A Evans; Roger J Summers
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

3.  Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.

Authors:  James G Ryall; Martin N Sillence; Gordon S Lynch
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

4.  Beta3-adrenoceptor agonist stimulation of the Na+, K+ -pump in rat skeletal muscle is mediated by beta2- rather than beta3-adrenoceptors.

Authors:  K T Murphy; H Bundgaard; T Clausen
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

5.  Biphasic effects of the beta-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle.

Authors:  Y L Liu; M A Cawthorne; M J Stock
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

6.  Acute effects of the beta 3-adrenoceptor agonist, BRL 35135, on tissue glucose utilisation.

Authors:  Y L Liu; M J Stock
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

7.  Characterization of beta-adrenoceptor mediated smooth muscle relaxation and the detection of mRNA for beta1-, beta2- and beta3-adrenoceptors in rat ileum.

Authors:  S J Roberts; M Papaioannou; B A Evans; R J Summers
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

8.  Mouse beta 3a- and beta 3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways.

Authors:  Dana S Hutchinson; Tore Bengtsson; Bronwyn A Evans; Roger J Summers
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

9.  Characterization and localization of atypical beta-adrenoceptors in rat ileum.

Authors:  S J Roberts; F D Russell; P Molenaar; R J Summers
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

10.  Classical and atypical binding sites for beta-adrenoceptor ligands and activation of adenylyl cyclase in bovine skeletal muscle and adipose tissue membranes.

Authors:  M N Sillence; M L Matthews
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.